| Rocatinlimab | KHK-4083; AMG-451 | Phase 3 Clinical | Amgen Inc, Kyowa Hakko Kirin Co Ltd | Abdominal Pain; Asthma; Autoimmune Diseases; Colitis; Colitis, Ulcerative; Colonic Diseases; Dermatitis, Atopic; Digestive System Diseases; Gastrointestinal Diseases; Inflammatory Bowel Diseases; Intestinal Diseases; Prurigo Nodularis | Details |
| Ivuxolimab | PF-8600; PF-04518600 | Phase 3 Clinical | Pfizer Inc | Bone metastases; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Leukemia, Myeloid, Acute; Lymphoma, Follicular; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Triple Negative Breast Neoplasms | Details |
| INBRX-106 | INBRX-106; ES-102; ES102 | Phase 3 Clinical | Inhibrx | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Head and Neck Neoplasms; Melanoma; Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| GSK3174998 | GSK3174998; GSK 3174998; GSK-3174998 | Phase 2 Clinical | Glaxosmithkline Plc | Multiple Myeloma; Neoplasms | Details |
| Telazorlimab | GBR-830; ISB-830 | Phase 2 Clinical | Glenmark Pharmaceuticals Ltd | | Details |
| Tavolimab | MEDI-0562 | Phase 2 Clinical | Medimmune | Carcinoma, Ovarian Epithelial; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Melanoma; Neoplasms, Squamous Cell; Ovarian Neoplasms; Peritoneal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| HX-111 | HX-111; HX111 | Phase 2 Clinical | Hanx Biopharmaceuticals (Wuhan) Co Ltd | Hematologic Neoplasms; Lymphoma; Solid tumours | Details |
| CS-01 | CS01; CS-01 | Phase 2 Clinical | Zhongshan Constimulus Bio Co Ltd | | Details |
| Brivekimig | SAR-442970; SAR442970 | Phase 2 Clinical | Sanofi | Colitis, Ulcerative; Crohn Disease; Diabetes Mellitus, Type 1; Glomerulonephritis; Glomerulosclerosis, Focal Segmental; Hidradenitis Suppurativa; Inflammation; Nephrosis | Details |
| IMG-007 | IMG-007 | Phase 2 Clinical | | Alopecia Areata; Dermatitis, Atopic; Eczema | Details |
| BAT-6026 | BAT-6026 | Phase 2 Clinical | Bio-Thera Solutions Ltd, Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | Autoimmune Diseases; Dermatitis, Atopic; Solid tumours | Details |
| Gimistotug | BGB-A445 | Phase 2 Clinical | BeOne Medicines Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Melanoma; Nasopharyngeal Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| Recombinant human anti-OX40 monoclonal antibody (Livzon Group) | | Phase 1 Clinical | Livzon Pharmaceutical Group Inc | | Details |
| SL-279252 | TAK-252; SL-279252 | Phase 1 Clinical | Shattuck Labs Inc, Takeda Pharmaceutical Co Ltd | Adenocarcinoma; Astrocytoma; Carcinoma, Basosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| FS-120 | FS-120 | Phase 1 Clinical | F-Star | Neoplasm Metastasis; Neoplasms | Details |
| Cudarolimab | IBI-101 | Phase 1 Clinical | | | Details |
| Revdofilimab | ABBV-368; PR-1628103 | Phase 1 Clinical | Abbvie Inc | Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Neoplasms; Solid tumours; Triple Negative Breast Neoplasms | Details |
| SHR-1806 | SHR-1806 | Phase 1 Clinical | Jiangsu Hengrui Medicine Co Ltd, Suzhou Suncadia Biopharmaceuticals Co Ltd | | Details |
| BMS-986178 | BMS-986178 | Phase 1 Clinical | Bristol-Myers Squibb Company | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Neoplasms; Solid tumours; Waldenstrom Macroglobulinemia | Details |
| EMB-09 | EMB-09 | Phase 1 Clinical | Shanghai Epimab Biotherapeutics, Inc | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Hepatitis B, Chronic; Melanoma; Nasopharyngeal Carcinoma; Neoplasms; Ovarian Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details |
| PeptiCRAd-1 | Valo-D102; PeptiCRAd-1 | Phase 1 Clinical | Valor Biotherapeutics | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Liposarcoma, Myxoid; Neoplasms; Osteosarcoma; Sarcoma; Sarcoma, Synovial; Skin Melanoma; Triple Negative Breast Neoplasms | Details |
| Cenzestotug | YH-002 | Phase 1 Clinical | | | Details |
| SAR-446422 | SAR446422; SAR-446422 | Phase 1 Clinical | Sanofi | | Details |
| STAR-0310 | ISB-830-X8; STAR-0310; STR-310 | Phase 1 Clinical | Ichnos Sciences Inc | | Details |
| HFB-3010 | HFB-301001; HFB-3010 | Phase 1 Clinical | HiFiBiO Therapeutics | Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Melanoma; Sarcoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Uterine Neoplasms | Details |
| HLX-51 | HLX-51 | Phase 1 Clinical | | | Details |
| MEDI-6469 | MEDI-6469; AGX-051 | Phase 1 Clinical | AgonOx Inc, Astrazeneca Plc, Providence Cancer Center, Providence Health & Services | Colorectal Neoplasms; Head and Neck Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphoma; Melanoma; Metastatic breast cancer; Neoplasms; Prostatic Neoplasms; Solid tumours | Details |
